NYSE:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $2.10 -0.10 (-4.34%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Inhibikase Therapeutics Stock (NYSE:IKT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IKT alerts:Sign Up Key Stats Today's Range$2.03▼$2.2350-Day Range$1.92▼$3.2652-Week Range$1.12▼$4.20Volume210,836 shsAverage Volume223,789 shsMarket Capitalization$145.31 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingModerate Buy Company OverviewInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Read More… Remove Ads Inhibikase Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreIKT MarketRank™: Inhibikase Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 838th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingInhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Inhibikase Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IKT. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IKT. News and Social Media1.7 / 5News Sentiment0.12 News SentimentInhibikase Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inhibikase Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 3 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.59% of the stock of Inhibikase Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.81% of the stock of Inhibikase Therapeutics is held by institutions.Read more about Inhibikase Therapeutics' insider trading history. Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IKT Stock News HeadlinesInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29 at 4:22 AM | markets.businessinsider.comHC Wainwright Reiterates "Neutral" Rating for Inhibikase Therapeutics (NYSE:IKT)March 29 at 3:43 AM | americanbankingnews.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 1, 2025 | Porter & Company (Ad)Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSOFebruary 24, 2025 | markets.businessinsider.comInhibikase Announces Expansion of Senior Leadership TeamFebruary 24, 2025 | globenewswire.comInhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | finanznachrichten.deInhibikase Therapeutics appoints Mark Iwicki as CEOFebruary 18, 2025 | markets.businessinsider.comSee More Headlines IKT Stock Analysis - Frequently Asked Questions How have IKT shares performed this year? Inhibikase Therapeutics' stock was trading at $3.25 at the start of the year. Since then, IKT stock has decreased by 35.5% and is now trading at $2.0950. View the best growth stocks for 2025 here. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NYSE:IKT) posted its quarterly earnings data on Monday, November, 15th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.24. The firm had revenue of $0.33 million for the quarter. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibikase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings11/15/2021Today4/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:IKT CIK1750149 Webwww.inhibikase.com Phone678-392-3419FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+211.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,030,000.00 Net MarginsN/A Pretax Margin-22,978.75% Return on Equity-350.63% Return on Assets-201.82% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$260,000.00 Price / Sales557.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book1.17Miscellaneous Outstanding Shares69,362,000Free Float66,178,000Market Cap$144.97 million OptionableNot Optionable Beta1.04 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSE:IKT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.